Literature DB >> 23478846

Brain regions associated with cognitive impairment in patients with Parkinson disease: quantitative analysis of cerebral blood flow using 123I iodoamphetamine SPECT.

Naoya Hattori1, Ichiro Yabe, Kenji Hirata, Tohru Shiga, Ken Sakushima, Sachiko Tsuji-Akimoto, Hidenao Sasaki, Nagara Tamaki.   

Abstract

PURPOSE: Cognitive impairment is a representative neuropsychiatric presentation that accompanies Parkinson disease (PD). The purpose of this study was to localize the cerebral regions associated with cognitive impairment in patients with PD using quantitative SPECT. PATIENTS AND METHODS: Thirty-two patients with PD (mean [SD] age, 75 [8] years; 25 women; Hoehn-Yahr scores from 2 to 5) underwent quantitative brain SPECT using 123I iodoamphetamine. Parametric images of regional cerebral blood flow (rCBF) were spatially normalized to the standard brain atlas. First, voxel-by-voxel comparison between patients with PD with versus without cognitive impairment was performed to visualize overall trend of regional differences. Next, the individual quantitative rCBF values were extracted in representative cortical regions using a standard region-of-interest template to compare the quantitative rCBF values.
RESULTS: Patients with cognitive impairment showed trends of lower rCBF in the left frontal and temporal cortices as well as in the bilateral medial frontal and anterior cingulate cortices in the voxel-by-voxel analyses. Region-of-interest-based analysis demonstrated significantly lower rCBF in the bilateral anterior cingulate cortices (right, 25.8 [5.5] vs 28.9 [5.7] mL per 100 g/min, P < 0.05; left, 25.8 [5.8] vs 29.1 [5.7] mL per 100 g/min, P < 0.05) associated with cognitive impairment.
CONCLUSIONS: Patients with cognitive impairment showed lower rCBF in the left frontal and temporal cortices as well as in the bilateral medial frontal and anterior cingulate cortices. The results suggested dysexecutive function as an underlining mechanism of cognitive impairment in patients with PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23478846     DOI: 10.1097/RLU.0b013e3182873511

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

Review 1.  Can neuroimaging predict dementia in Parkinson's disease?

Authors:  Juliette H Lanskey; Peter McColgan; Anette E Schrag; Julio Acosta-Cabronero; Geraint Rees; Huw R Morris; Rimona S Weil
Journal:  Brain       Date:  2018-09-01       Impact factor: 13.501

2.  Effects of a physical fitness program on memory and blood viscosity in sedentary elderly men.

Authors:  H K Antunes; M T De Mello; R F Santos-Galduróz; J C F Galduróz; V Aquino Lemos; S Tufik; O F A Bueno
Journal:  Braz J Med Biol Res       Date:  2015-07-28       Impact factor: 2.590

3.  An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.

Authors:  Nawaz Hack; Sarah M Fayad; Erin H Monari; Umer Akbar; Angela Hardwick; Ramon L Rodriguez; Irene A Malaty; Janet Romrell; Aparna A Wagle Shukla; Nikolaus McFarland; Herbert E Ward; Michael S Okun
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

4.  Longitudinal thalamic white and grey matter changes associated with visual hallucinations in Parkinson's disease.

Authors:  Angeliki Zarkali; Peter McColgan; Louise Ann Leyland; Andrew John Lees; Rimona Sharon Weil
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-09-28       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.